“Balance” seems to be the keyword for the next drug pricing reform in FY2024. Japan now appears ready to seek a better balance between evaluating innovative medicines and taking tough measures against companies dependent on long-listed products (LLPs) and generic…
BUSINESS
Daiichi Sankyo’s HER3 ADC Enters PIII for EGFR-Mutated NSCLC
Daiichi Sankyo said on August 8 that the first patient has been dosed in a global PIII study testing patritumab deruxtecan (HER3-DXd), one of its three lead antibody-drug conjugate (ADC) assets, in certain patients with EGFR-mutated non-small cell lung cancer…
To read the full story
Related Article
BUSINESS
- Eisai Alzheimer’s Chief Says Lecanemab US Sales “Ahead of Expectations”
February 7, 2023
- Next Astellas CEO Says Weathering Xtandi Cliff Is His Biggest Mission
February 7, 2023
- Teijin Pharma Picks R&D Chief Taneda for President from April
February 7, 2023
- Mochida Abandons Antidepressant MD-120, Lexapro’s Pediatric Use
February 7, 2023
- Astellas’ April-December Sales Up 17% on FX Tailwind; Xtandi Slows in US but Brisk in Japan
February 7, 2023
Companies don’t plan to fail when it comes to recruitment, but many fail to plan. What happens if your marketing director resigns? A recruiting plan gives your organization the confidence in knowing that whatever happens, there is a process in…
Is policy intervention necessary for Japanese drug makers reliant on off-patent brand-name medicines? Many members of the health ministry’s key…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…